SCHEMBL17364271

SCHEMBL17364271

CCCCCC1(C(=O)Nc2cc(Cl)c(Cl)cc2CC(SC)(SC)C(=O)O)CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CETP P11597 18/20 0.48
ITGB1 P05556 2/20 0.38
ITGA4 P13612 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15135948 0.86 CETP (0.60) CETPITGB1ITGA4
SCHEMBL16163052 0.85 CETP (0.59) CETPITGB1ITGA4
SCHEMBL17364268 0.83 CETP (0.56) CETPITGB1ITGA4
SCHEMBL16163008 0.80 CETP (0.41) CETP
SCHEMBL17364272 0.79 CETP (0.36) CETP
SCHEMBL1897694 0.76 CETP (0.48) CETPITGB1ITGA4
SCHEMBL1524882 0.75 CETP (0.75) CETPITGB1ITGA4
SCHEMBL17364267 0.75 CETP (0.52) CETP
SCHEMBL13212755 0.73 CETP (0.78) CETPITGB1ITGA4
SCHEMBL1897198 0.70 CETP (0.63) CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150374675-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) 2015-12-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150374675-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX APOB, FABP3, PLTP CETP 5/4885ITGB1 2934/4885ITGA4 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.